MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC.

MLA

Azuma, K., et al. “MO1-2 Safety Profile of LIGHT-NING 3rd Interim Analysis: 1L Nivolumab + Ipilimumab +/− Chemotherapy for Metastatic NSCLC.” Annals of Oncology, vol. 35, Oct. 2024, p. S1328. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.07.515.

APA

Azuma, K., Imai, H., Yamaguchi, T., Kijima, T., Kishi, K., Fujita, K., Saito, H., Shiraishi, Y., Tanizaki, J., Takashima, Y., Tambo, Y., Watanabe, S., Hataji, O., Toi, Y., Fukuhara, T., Ohsugi, T., Kuroda, H., Ohe, Y., & Horinouchi, H. (2024). MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC. Annals of Oncology, 35, S1328. https://doi.org/10.1016/j.annonc.2024.07.515

Chicago

Azuma, K., H. Imai, T. Yamaguchi, T. Kijima, K. Kishi, K. Fujita, H. Saito, et al. 2024. “MO1-2 Safety Profile of LIGHT-NING 3rd Interim Analysis: 1L Nivolumab + Ipilimumab +/− Chemotherapy for Metastatic NSCLC.” Annals of Oncology 35 (October): S1328. doi:10.1016/j.annonc.2024.07.515.